Chardan Capital Initiates Avalanche Biotechnologies With Neutral

by Monica Gerson, Benzinga Staff Writer

February 19, 2015 9:04 AM | 12 seconds read | Make a Comment

Analysts at Chardan Capital initiated coverage on

Avalanche Biotechnologies, Inc.AAVL

with a Neutral rating. The target price for Avalanche Biotechnologies is set to $40. Avalanche Biotechnologies' shares rose 7.90% to close at $39.74 yesterday.

Market News and Data brought to you by Benzinga APIs

Posted In: Initiation Analyst Ratings Chardan Capital

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Chardan Capital Initiates Avalanche Biotechnologies With Neutral